India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed another inspection last month.

The drug is indicated for the treatment of alopecia areata - a condition in which the immune system attacks hair follicles, ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and ...

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for sev ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

The market needs to reclaim and sustain above the 20-day EMA to witness a further northward journey in the upcoming sessions.

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...